Alzheimers would be a stupid target for ANP !
A lot of money, a lot of time, large trials and a biotech graveyard with 99% failure rate - leave that stuff to big pharma with money to burn.
ANP’s best to stick with rare diseases which i think they will - as is we still need to finding the funding for the IIB trial.
Where others have failed will Atl1102 succeed ?, page-9
-
- There are more pages in this discussion • 557 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $83.73M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 7.9¢ | $153.8K | 1.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 927041 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 218878 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |